Agilon Health, Inc. (NYSE:AGL) Receives $2.71 Average Target Price from Analysts

Agilon Health, Inc. (NYSE:AGL) has received a consensus rating of “Hold” from the seventeen analysts that are currently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and four have given a buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $2.7083.

A number of brokerages recently commented on AGL. Wells Fargo & Company reduced their price target on Agilon Health from $1.50 to $1.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. BTIG Research reissued a “neutral” rating on shares of Agilon Health in a report on Friday, December 12th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Agilon Health in a research report on Wednesday, January 21st. Barclays lowered their price objective on Agilon Health from $1.50 to $1.00 and set an “underweight” rating for the company in a report on Thursday, November 6th. Finally, Zacks Research raised Agilon Health from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 21st.

Insider Transactions at Agilon Health

In other Agilon Health news, Director John William Wulf acquired 81,000 shares of the firm’s stock in a transaction on Wednesday, November 12th. The stock was purchased at an average price of $0.63 per share, with a total value of $51,030.00. Following the completion of the acquisition, the director directly owned 365,857 shares in the company, valued at $230,489.91. This trade represents a 28.44% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 3.57% of the stock is owned by company insiders.

Hedge Funds Weigh In On Agilon Health

Several hedge funds and other institutional investors have recently modified their holdings of AGL. Wealthcare Advisory Partners LLC bought a new stake in shares of Agilon Health during the third quarter valued at approximately $26,000. Arrowpoint Investment Partners Singapore Pte. Ltd. bought a new stake in shares of Agilon Health during the 2nd quarter worth $31,000. Krilogy Financial LLC acquired a new position in shares of Agilon Health in the 4th quarter worth $34,000. CIBC Bancorp USA Inc. purchased a new stake in shares of Agilon Health during the third quarter valued at $34,000. Finally, Merit Financial Group LLC acquired a new position in shares of Agilon Health in the 4th quarter valued at $35,000.

Trending Headlines about Agilon Health

Here are the key news stories impacting Agilon Health this week:

• Negative Sentiment: Multiple firms have filed or announced class‑action investigations alleging securities fraud and urging affected investors to contact counsel — heightening legal and financial uncertainty for AGL. The Gross Law Firm notice
• Negative Sentiment: The DJS Law Group announced an investigation into Agilon for securities‑fraud violations, signaling more potential plaintiff activity and discovery requests that can be costly and disruptive. DJS Law Group announcement
• Negative Sentiment: Several national firms (Levi & Korsinsky, Block & Leviton, Rosen, Faruqi & Faruqi, Kirby McInerney, Pomerantz, Bronstein Gewirtz & Grossman, Frank R. Cruz, etc.) have issued investor alerts or filed complaints and reminded investors of a March 2, 2026 lead‑plaintiff deadline — reinforcing the narrative of broad legal exposure. Levi & Korsinsky alert
• Negative Sentiment: Block & Leviton and other firms specifically note a filed securities‑fraud suit and are soliciting potential lead plaintiffs, which may accelerate litigation activity and settlement negotiations. Block & Leviton notice
• Negative Sentiment: Rosen Law Firm and Faruqi & Faruqi have publicized first‑filed claims and reminders about the March 2 deadline — suggesting coordinated plaintiff interest that could increase case visibility and potential damages exposure. Rosen Law Firm notice

Agilon Health Price Performance

NYSE AGL traded down $0.03 on Thursday, reaching $0.66. The company had a trading volume of 312,710 shares, compared to its average volume of 6,160,506. The firm has a market capitalization of $271.96 million, a PE ratio of -0.87 and a beta of 0.06. The firm has a 50-day moving average of $0.79 and a 200-day moving average of $0.99. Agilon Health has a 1 year low of $0.51 and a 1 year high of $6.08.

Agilon Health (NYSE:AGL) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.09). Agilon Health had a negative return on equity of 75.92% and a negative net margin of 5.24%.The firm had revenue of $1.44 billion for the quarter, compared to analysts’ expectations of $1.43 billion. As a group, sell-side analysts expect that Agilon Health will post -0.59 EPS for the current fiscal year.

About Agilon Health

Agilon Health (NYSE: AGL) is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.

Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.